Fig. 3From: Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancerDose-response curve of doxorubicin. a-b PN-transfection experiment. c-d rPN treatment experiment. M = mock transfected, PN = PN-transfected, error bar determined SEM, * = P-value < 0.05 and ** = P-value < 0.001Back to article page